Core Insights - Huate Dain (stock code: 000915) reported a revenue of 1.17 billion yuan for the first half of 2025, representing a year-on-year growth of 1.39% [1][2] - The net profit attributable to shareholders was 337 million yuan, an increase of 1.69% compared to the same period last year [1][2] - The net cash flow from operating activities reached 674 million yuan, showing a significant increase of 61.44% year-on-year [1][2] Financial Performance - Revenue for the reporting period: 1,170,478,273.18 yuan, up from 1,154,413,477.20 yuan, a growth of 1.39% [2] - Net profit attributable to shareholders: 337,467,373.75 yuan, compared to 331,871,287.24 yuan last year, an increase of 1.69% [2] - Net profit after deducting non-recurring gains and losses: 332,340,551.27 yuan, up 4.31% from 318,600,238.57 yuan [2] - Basic and diluted earnings per share: 1.44 yuan, a slight increase of 1.41% from 1.42 yuan [2] - Weighted average return on equity: 10.96%, an increase of 0.15 percentage points from 10.81% [2] Asset Overview - Total assets at the end of the reporting period: 4,596,433,238.58 yuan, down 6.78% from 4,930,936,591.73 yuan at the end of the previous year [2] - Net assets attributable to shareholders: 2,780,455,844.63 yuan, a decrease of 4.51% from 2,911,651,440.88 yuan [2] Business Segments - The primary revenue and profit source for Huate Dain is its subsidiary, Dain Pharmaceutical, which achieved a revenue of 1.15 billion yuan in the first half of 2025, accounting for 98.59% of the company's consolidated revenue [1][2] - Dain Pharmaceutical's key children's products include Yikexin, YDxin, Dain Iron, Dain Calcium, Dain Zinc, and others, with Yikexin being a well-known trademark in China [2] Brand Value and Market Position - In the first half of 2025, Dain Pharmaceutical was listed among the "2025 China Brand 500 Strong" with a brand value of 231.26 billion yuan, and its flagship product Yikexin was valued at 49.82 billion yuan [3] - The company is focused on children's clinical needs and is developing multiple products in respiratory and mental health fields, with four new projects submitted for approval in 2025 [3] Company Background - Established in 1993 and listed on the Shenzhen Stock Exchange in 1999, Huate Dain has a registered capital of 234 million yuan, with Shandong Huate Holding Group as the largest shareholder [3] - The company operates as a national-level comprehensive new drug research and development platform, with several innovation centers dedicated to children's medication [3]

| 山东华特达因健康股份有限公司 | | | --- | --- | | 二〇二五年半年度报告全文 | | | 二〇二五年八月编制 山东华特达因健康股份有限公司 | 2025 年半年度报告全文 | | 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 | | | 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 | | | 个别和连带的法律责任。 | | | 公司负责人朱效平、主管会计工作负责人谭立富及会计机构负责人（会 | | | 计主管人员）刘稳声明：保证本半年度报告中财务报告的真实、准确、完整。 | | | 所有董事均已出席了审议本次半年报的董事会会议。 | | | 本半年度报告涉及对公司未来发展的描述等前瞻性陈述，不构成公司对投 | | | 资者的实质承诺，请投资者注意投资风险。 | | | 本公司请投资者认真阅读本报告全文，并特别注意报告第三节"管理层讨 | | | 论与分析"中"公司面临的风险和应对措施"部分的描述。 | | | 2025 年 6 月 公司经本次董事会审议通过的利润分配预案为：以 | 30 日总 | | 股本 234,331,485 股为基数，向全体 ...